Mission Statement
Boulder BioScience’s mission is to develop new therapeutic interventions for thrombotic disease. Our immediate goal is to leverage scientific discoveries and new formulation technology into the rapid clinical development of a new API for treating Acute Ischemic Stroke (AIS). Our lead drug candidate delivers a small molecule neuroprotector and immune modulator already supported by pre-clinical safety data and early clinical trial development. The drug candidate has a unique mechanism of action to modulate overactive innate immunity, reducing ischemic and neutrophil-related brain damage in AIS.
The Boulder BioScience leading drug candidate provides a small molecule API achieving sufficient oral bioavailability for AIS treatment. The API is an immune modulator that has already completed extensive pre-clinical safety evaluation and early clinical development. The oral drug candidate has a unique mechanism of action to control unwanted, inflammatory immune system damage to the brain. The API is associated with well-established neuroprotective mechanisms in pre-clinical models of thrombosis, cerebral hypoxia, and brain hemorrhage relevant to AIS. For further information, please email [email protected].